Short Interest in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Rises By 6.0%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 6,000,000 shares, an increase of 6.0% from the December 15th total of 5,660,000 shares. Based on an average daily volume of 250,800 shares, the days-to-cover ratio is currently 23.9 days. Currently, 31.2% of the company’s stock are short sold.

Dianthus Therapeutics Stock Up 4.1 %

Shares of DNTH stock opened at $20.00 on Tuesday. The stock’s 50-day moving average price is $23.47 and its 200 day moving average price is $26.36. The stock has a market capitalization of $592 million, a PE ratio of -8.00 and a beta of 1.74. Dianthus Therapeutics has a 52-week low of $10.65 and a 52-week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on DNTH shares. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Oppenheimer upped their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Finally, TD Cowen assumed coverage on Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating for the company. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $46.43.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC boosted its holdings in shares of Dianthus Therapeutics by 9.2% in the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock valued at $210,000 after acquiring an additional 814 shares in the last quarter. Quest Partners LLC boosted its holdings in Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after purchasing an additional 1,124 shares in the last quarter. Fred Alger Management LLC increased its position in Dianthus Therapeutics by 52.5% during the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after purchasing an additional 3,316 shares during the period. MetLife Investment Management LLC raised its stake in shares of Dianthus Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock worth $382,000 after buying an additional 7,854 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Dianthus Therapeutics by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after buying an additional 8,473 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.